Item 8.01 Other Events.

On April 20, 2021, Kindred Biosciences, Inc. ("KindredBio") issued a press release announcing positive results in a new long-acting interleukin (IL)-31 antibody program (KIND-039) that integrates KindredBio's novel half-life extension technology. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.




Item 9.01  Financial Statements and Exhibits.
Exhibit No.                 Description
        99.1                  Press Release of Kindred Biosciences, Inc. issued on     April 20    ,
                            2021
        104                 Cover Page Interactive Data File (embedded within the Inline XBRL
                            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses